GCF Newsletter : November 2017

Our November 17th annual A Cause for Hope fundraising event has received an overwhelming response. Tickets are sold out.

You can still be a part of the evening’s success – and help fund gastric cancer research – by making a donation today.

Thank you for your support!

Follow Us During Gastric Cancer Awareness Month

This month, tune in on  Facebook and Twitteras we share short video updates announcing new developments in our Gastric Cancer Registry at Stanford. Expanded Registry initiatives will be launched in 2018, including new collaborations with Intermountain Health, four states, and a major university in Korea, where gastric cancer is highly prevalent. These partnerships will help make this important resource more accessible to patients and researchers everywhere to bring us closer to a cure.
Watch this sneak peek from Hanlee Ji, MD, of Stanford University, about the outlook for the updated Registry.

 

Recipes for Your Thanksgiving Table

Need inspiration over the holidays? Here are a variety of resources that will help you prepare for Thanksgiving and develop a nutritional plan to support your health:
  • Lilly Oncology has recently launched StomachCancerWellness.com – a new hub for stomach cancer nutrition resources. The site presents a digital version of the Viver Health “Guide for Wellness with Stomach Cancer.”

Research Highlights for Gastric Cancer

There truly is A Cause for Hope with the number of new developments in treatments for gastric cancer patients being announced each month. In the past 30 days, experts on Oncology Live have discussed  the growth of immunotherapy in gastric cancer and how international cooperation among specialistsis crucial to the advancement of care for gastric cancer patients. Meanwhile, the Lancet has published a phase III randomized controlled trial evaluating the efficacy of the PD-1 inhibitor, Nivolumab, in patients with previously treated advanced gastric cancer. The finding found that Nivolumab improved overall survival compared with the placebo. And the first gastric cancer patient is receiving doses in the clinical trial collaboration evaluating Halozyme’s PEGPH20 with anti-PDL1 immunotherapy.

 

Thank You to Our Corporate Sponsors:

 

National Sustaining Sponsor

 

“A Cause For Hope” Event Sponsors:

Gold Sponsor

Silver Sponsors

SHARE